

Quantitative proteomic analysis of the miR-148a-associated mechanisms of metastasis in non-small cell lung cancer

DANDAN CHU*, JING LI*, HECHUN LIN, XIAO ZHANG, HONGYU PAN,
LEI LIU, TAO YU, MINGXIA YAN and MING YAO

State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital,
Shanghai Jiao Tong University School of Medicine, Shanghai 200032, P.R. China

Received December 14, 2016; Accepted October 13, 2017

DOI: 10.3892/ol.2018.8581

Abstract. MicroRNAs (miRs) are small non-coding RNAs that regulate gene expression and protein synthesis. Our previous study demonstrated that miR-148a suppressed the metastasis of non-small cell lung cancer (NSCLC) *in vitro* and *in vivo*. However, the modulatory mechanism of this effect remains unclear. In the present study, quantitative proteomic technology was used to study the protein expression profile of SPC-A-1 cells subsequent to the downregulation of miR-148a expression, in order to elucidate the molecular mechanism of the suppression of NSCLC metastasis by miR-148a. The differentially expressed proteins identified were analyzed using bioinformatics tools, including the Database for Annotation, Visualization and Integrated Discovery and the Search Tool for the Retrieval of Interacting Genes/proteins. In two experiments, 4,048 and 4,083 proteins were identified, and 4,014 and 4,039 proteins were quantified, respectively. In total, 44 proteins were upregulated and 40 proteins were downregulated. This was verified at the protein and mRNA levels by western blotting and reverse transcription-quantitative polymerase chain reaction, respectively. Bioinformatics analysis was used to identify potential interactions and signaling networks for the differentially expressed proteins. This may have provided an appropriate perspective for the comprehensive analysis of the modulatory mechanism underlying the metastasis-suppressive effects of miR-148a in NSCLC. In conclusion, quantitative proteomic technology revealed that miR-148a may regulate a panel of tumor-associated proteins to suppress metastasis in NSCLC.

Introduction

Lung cancer is the leading cause for cancer-associated mortality worldwide (1,2). Despite considerable improvements in diagnosis and chemotherapy, and the development of molecularly-targeted treatments, the survival rate for lung cancer remains low; the 5-year survival rate is <20% (3). Non-small cell lung cancer (NSCLC) is responsible for >80% of the cases of lung cancer-associated mortality (4). One reason for the poor prognosis of lung cancer is metastasis, which presents a major challenge in the treatment of NSCLC (5). To overcome this challenge, the elucidation of the molecular mechanism underlying NSCLC metastasis is required.

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate the translation of mRNA or induce target gene mRNA degradation (6,7). Accumulating evidence suggests that miRNAs are associated with a number of cellular biological processes, including proliferation, apoptosis, drug resistance and metastasis. Regarding the role of miRNAs in cancer, a number of potential therapeutic targets were previously identified (8-10). The mechanisms underlying the effects of miRNAs is a longstanding research topic, and a number of studies have aimed to identify the target signaling pathways of cancer-associated miRNAs (11,12).

Proteomics is an emerging field that offers a wide range of opportunities to investigate the malignancy-associated molecular alterations at the protein level, and is thus being increasingly applied in cancer research (13). Isobaric labeling reagents are peptide tags that produce tandem mass spectrometry (MS/MS) spectrum-specific fragment ions, used for MS/MS quantification (14). Isobaric Tag for Relative and Absolute Quantitation (iTRAQ) labeling technology combined with nano liquid chromatography-mass spectrometry (NanoLC-MS/MS) has been employed effectively for biomarker discovery (15). As miRNAs not only induce alterations of the protein expression level of their target genes, but also indirectly change the expression of a range of proteins through interactions with target proteins, cancer research is turning to proteomics-based strategies to seek the putative targets and further molecular mechanisms modulated by miRNAs (16-18).

Our previous study (19) demonstrated that miR-148a exerted metastasis-suppressive effects on NSCLC. However, the molecular mechanisms underlying the

Correspondence to: Dr Mingxia Yan or Dr Ming Yao, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 25/Ln 2200, Xietu Road, Shanghai 200032, P.R. China
E-mail: mingxia_yan@126.com
E-mail: myao@shsci.org

*Contributed equally

Key words: microRNA-148a, proteomic, non-small cell lung cancer, metastasis, bioinformatics analysis

metastasis-suppressive effects of miR-148a on NSCLC remain uncharacterized. In the present study, iTRAQ labeling technology and NanoLC-MS/MS were used to analyze the whole protein profiles of SPC-A-1 lung adenocarcinoma cells following transfection with the miR-148a inhibitor. The data may provide a general perspective for the analysis of the metastasis-modulatory mechanism of miR-148a in NSCLC.

Materials and methods

Cell lines and cell culture. SPC-A-1 human lung adenocarcinoma cells were obtained from the Cellular Institute of the Chinese Academy of Science (Shanghai, China). The SPC-A1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (Biowest, Nuaille, France), 100 U/ml penicillin sodium and 100 mg/ml streptomycin sulfate at 37°C in a humidified atmosphere containing 5% CO₂.

Oligonucleotide transfection. An miR-148a inhibitor (miR20000243) and negative control (miR02101-1-5) were synthesized by Guangzhou RiboBio Ltd. (Guangzhou, China). On day 1, 5x10⁴ cells were seeded into a 6-well plate and were transfected on day 2 with the miRNA inhibitor or a control oligonucleotide using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's instructions. Cells were collected at 48 h after transfection for RNA extraction and protein preparation.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays. miRNA was extracted from the transfected cells using a mirVana miRNA Isolation kit (Ambion, Thermo Fisher Scientific, Inc.). The expression level of mature miR-148a was quantified with specific primers (Guangzhou RiboBio Ltd.) according to the manufacturer's instructions. RT-qPCR was performed using miRNA RT-qPCR Starter kit (Guangzhou RiboBio Ltd.) and normalized to U6 small nuclear RNA. U6 primers were synthesized in Guangzhou RiboBio Ltd. The RT reaction conditions were as follows: 42°C for 60 min, 70°C for 10 min. The PCR was conducted based on following conditions: pre-denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 2 sec, annealing at 60°C for 20 sec, and extension at 70°C for 10 sec.

Total RNA was extracted from transfected cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions, and was quantified using a NanoDrop 2000 spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). First-strand cDNA was synthesized with a PrimeScript RT Reagent kit and RT-qPCR was performed with SYBR Green Premix Ex Taq (both from Takara Bio, Inc., Otsu, Japan) using β -actin as an endogenous control. The primers were synthesized by Genewiz, Inc. (South Plainfield, NJ, USA), and the sequences are presented in the Table I. The RT reaction conditions were as follows: 37°C for 45 min, 85°C for 5 sec. While the PCR was conducted based on following conditions: pre-denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 5 sec, annealing and extension at 60°C for 31 sec.

The relative expression level of miR-148a and differentially expressed gene were analyzed using the comparative Cq method (20).

Protein preparation. All protein extraction procedures were performed on ice. The cell pellets were dissociated in lysis buffer (Pierce; Thermo Fisher Scientific, Inc.) supplemented with protease and phosphatase inhibitors, followed by 40 min incubation on ice. The lysate was centrifuged at 12,000 x g for 15 min at 4°C, and the supernatants were collected. The protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions, using bovine serum albumin (Roche Diagnostics, Basel, Switzerland) as the standard.

iTRAQ labeling. The following iTRAQ experiments were performed as described previously (15), with some modifications. iTRAQ labeling was achieved using an iTRAQ Reagent 4-Plex kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The cell lysates of SPC-A1 cells transfected with the control or miR-148a inhibitor were labeled with iTRAQ labeling reagents 116 and 117, respectively. In brief, 100 μ g lysate from each sample was reduced with tris-(2-carboxyethyl) phosphine, alkylated with methyl methanethiosulfonate (MMTS) and digested overnight at 37°C using trypsin (mass spectrometry grade; Promega Corporation, Madison, WI, USA) at a trypsin to protein ratio of 1:20 (w/w). The iTRAQ labeled samples were combined and transferred into a 1.5 ml tube, desalted with Oasis HLB cartridges (Waters Corporation, Milford, MA, USA) and dried in a vacuum centrifuge (Concentrator Plus; Eppendorf, Hamburg, Germany) at 45°C for 1 h, 60°C for 1 to 2 h. The iTRAQ workflow is illustrated in Fig. 1A.

Strong cation exchange (SCX). The iTRAQ-labeled peptides were fractionated by SCX chromatography using a 20AD HPLC system (Shimadzu Corporation, Kyoto, Japan) and a polysulfethyl column (2.1x100 mm, 5 μ m, 200 Å; The Nest Group, Inc., Southborough, MA, USA). The peptide mixture was dissolved in 80 μ l buffer A [10 mM KH₂PO₄ in 25% acetonitrile (ACN; pH 3.0); Thermo Fisher Scientific, Inc.] and loaded onto the column. The peptides were separated in a gradient of 0-80% buffer B (as buffer A, with the addition of 350 mM KCl) at a flow rate of 200 μ l/min over 60 min. A total of 20 RP fractions were collected, desalted using C18 cartridges (UltraMicroSpin; The Nest Group, Inc.), dried and reconstituted using 20 μ l 0.1% formic acid (FA) for NanoLC-MS/MS analysis.

NanoLC-MS/MS analysis. A NanoLC system (NanoLC-2D Ultra; Eksigent Technologies, Dublin, CA, USA) combined with a Triple TOF 5600 mass spectrometer (AB Sciex LLC, Framingham, MA, USA) were utilized for analysis. The peptides were enriched on a reversed-phase trap column (ProteoPepII C18 column, 5 μ m, 300 Å, 0.15x25 mm; New Objective IntegraFrit; Scientific Instrument Services, Inc., Ringoes, NJ, USA) and eluted onto an analytical column (ProteoPep C18 column, 5 μ m, 300 Å, 0.075x150 mm; New Objective IntegraFrit; Scientific Instrument Services, Inc.). The NanoLC

Table I. Primer sequences used in experiments.

Genes	Forward	Reverse
MYH9	GACAGCCAGAGCGTTAGAGG	AGACCAGTGAGGACGAGCTA
CD44	CCTCCCTCCGTCTTAGGTCA	ATTCAAATCGATCTGCGCCA
ITGB1	CCGCGCGGAAAAGATGAAT	ATGTCATCTGGAGGGCAACC
LAMB3	GGGAGACCCCCACATTCAAG	GCAGGGGCAAAACACAAGAGG
PHGDH	CTGGCCAGGCAGATTCCC	AGAGGCCAGATCTCCTCCAG
ACTN4	TGACAAGCTGAGGAAGGACG	ATTATGGCCTTCTCGTCGGG
LMNA	ATCGCTTGCGGCTCTACATC	TTGGTATTGCGCGCTTTCAG
VIM	GGACCAGCTAACCAACGACA	AAGGTCAAGACGTGCCAGAG
PSMA7	GTGTGCGCTTTTGAGAGTCG	TCTTCCTCGAACCAACCG
MTHFD1	TCCAGTAGTAGTGCCGTGA	GCTTTGTGTTGAGCTTCGGG
GSTM3	TGCACAGTTGGAGAGAGCAG	TGTACACAGGACGGTTTCCG
FH	AGCCGCCCAGAAATTCTACC	TTTTGGCTTGCCATTTCGAGC
HSPB1	CGCGGAAATACACGCTGC	CGGATTTTGCAGCTTCTGGG
LRPPRC	TGGCCGGAGGACTACTGAG	GCAAGGCATGACTACCACCT
CPT2	AAGAAGCAGCAATGGGCCAG	AGGGTCCAGGTAGAGCTCAG
IDH2	TTTGCAACGCCATAGGCTTC	CTCATCAGGGGTGATGGTGG
β -actin	TTGTTACAGGAAGTCCCTTGCC	ATGCTATCACCTCCCCTGTGTG

gradient was 5-35% buffer C (98% ACN, 2% H₂O, 0.1% FA) over 120 min at a flow rate of 300 nl/min. The MS analysis was performed in the positive-ion mode with a nano ion spray voltage being typically maintained at 2.3 kV and a scan range of 350 to 1,500 (m/z). Full-scan MS spectra were acquired from 40 precursors selected for MS/MS from the 100-1,500 m/z range, utilizing a dynamic exclusion of 30 sec. The IDA collision energy (CE) parameter script, selecting up to 40 precursors with charge states of 2⁺ to 4⁺, controlled the CE automatically. The tryptic peptides of β -galactosidase were used to calibrate the mass spectrometer.

Protein identification and quantification. Analysis of the proteins was performed using ProteinPilot 4.1 software (AB Sciex). The search parameters were specified as follows: i) Sample type, iTRAQ 4-plex (peptide-labeled); ii) cysteine alkylation, MMTS; iii) digestion, trypsin; iv) instrument, TripleTOF 5600; v) special factors, none; vi) species, *Homo sapiens*; vii) ID Focus, biological modifications; viii) database, UniProtKB/Swiss-Prot FASTA (as released in November 2013 with 176,592 human sequences); and ix) search effort, thorough ID. The peptides for iTRAQ quantitation were automatically chosen by the Pro Group™ algorithm from the ProteinPilot software to calculate the reporter peak area and the false discovery rate (FDR) using a reverse database search strategy. A qualification criterion of unused confidence score >1.3 was enforced, corresponding to a peptide confidence level of 95%. When the iTRAQ ratios were >1.5 or <0.67 between the SPC-A-1 cells transfected with the control miR and with the miR-148a inhibitor, the protein expression levels were considered to be differential.

Western blotting (WB). A total of 20 μ g of protein samples from the collected cells were loaded onto 8-12% SDS-PAGE gels and transferred onto nitrocellulose filter membranes

(EMD Millipore, Billerica, MA, USA). Subsequent to blocking (20°C for 1 h) in 5% non-fat milk in PBS, the membranes were incubated overnight at 4°C with rabbit primary antibodies against the following: DNA methyltransferase 1 (DNMT1, dilution 1:500, D160261), matrix metalloproteinase 15 (MMP15, 1:500 dilution, D120991), Rho-associated protein kinase 1 (ROCK1, 1:1,000 dilution, D221198), sphingosine-1-phosphate receptor 1 (S1PR1, 1:500 dilution, D161195), cholecystokinin B receptor (CCKBR, 1:500 dilution, D160389), WNT1 (1:200 dilution, D261302), (MMP7, 1:500 dilution, D120096), actinin α 4 (ACTN4, 1:500 dilution, D221929), fumarate hydratase (FH, 1:500 dilution, D222390), heat shock protein β 1 (HSPB1, 1:500 dilution, D163024), lactate dehydrogenase (LDHB, 1:1,000 dilution, D151002), fatty acid synthase (FASN, 1:200 dilution, D190620) and catalase (CAT, 1:500 dilution, D122036) (all from BBI Life Sciences Corporation, Shanghai, China), vimentin (VIM, 1:200 dilution, sc-5565) and laminin β 3 (LAMB3, 1:200 dilution, sc-20775) (both from Santa Cruz Biotechnology, Inc., Dallas, TX, USA), phosphoglycerate dehydrogenase (PHGDH; 1:200 dilution, AP2936c; Abgent, San Diego, CA, USA) and isocitrate dehydrogenase (NADP⁺) 2 (IDH2, 1:200 dilution, ab131263; Epitomics, Burlingame, CA, USA).

HRP-conjugated anti-rabbit IgG (1:5,000 dilution, A0545; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was used as the secondary antibody in which membranes were incubated at 20°C for 2 h. A total of 3 washes in PBS-Tween were performed following each antibody incubation. SuperSignal West Femto Maximum Sensitivity substrate (Thermo Fisher Scientific, Inc.) was used for the visualization of the proteins, and β -actin was used as a loading control (1:30,000 dilution, A3854; Sigma-Aldrich, Merck KGaA).

Statistical analysis. The differentially expressed proteins were input into the Database for Annotation, Visualization




Figure 1. Quantitative proteomic analysis experimental workflow and results. (A) SPC-A-1 cells were transfected with a miR-148a inhibitor or a control oligonucleotide. At 48 h, proteins of the transfected cells were digested with trypsin and labeled with the iTRAQ tags 116 and 117. The labeled peptides were then separated using offline strong cation exchange LC and analyzed using NanoLC-MS/MS. The experiment was performed in duplicate, and identified 44 upregulated/40 downregulated proteins, for a total of 84 differentially expressed proteins, which were then analyzed with bioinformatics. A number of the differentially expressed proteins were also verified with WB and RT-qPCR. (B) RT-qPCR quantification of miR-148a in the SPC-A-1 cells at 48 h after transfection. (C) Expression levels of miR-148a-associated proteins as determined by WB in the SPC-A-1 cells at 48 h after transfection, to demonstrate the downregulation of miR-148a at the functional level. β -actin served as an internal control. (D) Across the two MS experiments, a total of 4,934 proteins were identified, and 4,885 proteins were quantified, with the criteria of an unused protein score >1.3 and a number of peptides ≥ 2 . The label rate was 99.0% (4,885/4,934). miR, microRNA; iTRAQ, isobaric tag for relative and absolute quantitation; LC, liquid chromatography; MS, mass spectrometry; WB, western blotting; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; DNMT1, DNA methyltransferase 1; MMP15, matrix metalloproteinase 15; ROCK1, Rho associated protein kinase 1; S1PR1, sphingosine 1-phosphate receptor 1; CCKBR, cholecystokinin B receptor; MMP7, matrix metalloproteinase 7.

and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>) and the Search Tool for the Retrieval of Interacting genes/proteins (STRING; <http://string.embl.de>). The DAVID search tool was used for the Gene Ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the differentially expressed proteins, with a threshold of $P < 0.05$. STRING was used to predict protein-protein interactions with a weight score threshold of ≤ 0.4 .

Statistical analysis. t-tests performed with SPSS 19.0 software (IBM Corp., Armonk, NY, USA) were used to analyze differences between the protein profiles, the level of miR-148a expression and the mRNA expression of the differentially expressed proteins between the cells treated with a miR-148a inhibitor and the control. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Quantitative proteomic analysis of miR-148a-regulated downstream proteins. To identify downstream proteins regulated by miR-148a, global protein expression changes in the expression profile of SPC-A-1 cells transfected with a miR-148a inhibitor compared with SPC-A-1 cells transfected with a control oligonucleotide were identified using the iTRAQ-labeling proteomic approach.

The knockdown of miR-148a in SPC-A-1 cells was detected using RT-qPCR (Fig. 1B) and validated at a functional level by performing western blots for 7 well-established targets of miR-148a: DNMT1, MMP15, ROCK1, S1PR1, CCKBR, WNT-1 and MMP7, which were selected according to previous studies (21-26). No evident change was observed for DNMT1, MMP15 or ROCK1, whereas S1PR1, CCKBR, WNT1 and MMP7 expression levels were distinctly upregulated in SPC-A1 cells treated with the miR-148a inhibitor compared with SPC-A-1 cells treated with the control (Fig. 1C).

With the criteria of unused protein score >1.3 and number of peptides ≥ 2 , two iTRAQ experiments identified 4,048 and 4,083 proteins, as annotated with ProteinPilot software (global FDR, $<1\%$), and 4,014 and 4,039 proteins were quantified. Cumulatively, 4,934 proteins were identified and 4,885 proteins were quantified (Fig. 1D); the label rate was 99.0% (4,885/4,934). A total of 44 upregulated and 40 downregulated proteins were identified in the SPC-A-1 cells treated with the miR-148a inhibitor compared with the control cells ($P < 0.05$; Table II).

Cluster analysis of miR-148a-regulated downstream proteins. A heat map was generated for the 84 differentially expressed proteins subsequent to miR-148a inhibitor transfection (Fig. 2). The identified differentially expressed

Table II. Differentially expressed proteins in microRNA-148a inhibitor-transfected cells compared with control cells.

A, Upregulated differentially expressed proteins

Accession	Protein	Unused score	Coverage, % ^a	Peptide 95% CL ^a	iTRAQ rate ^a	P-value ^a
splQ09666	AHNAK	457.84±0.62	66.71±1.69	352.5±12.02	4.57±0.18	<0.0001
splP02545	LMNA	91.37±2.67	66.04±3.30	75.5±3.54	9.83±0.77	<0.0001
trlF5GZS6	SLC3A2	54.32±0.18	45.74±0.23	37.5±0.71	4.45±0.06	<0.0001
splO43707	ACTN4	130.18±3.61	71.84±4.11	167.5±7.78	2.54±0.80	<0.0001
splP35579	MYH9	222.67±10.28	59.18±2.38	319.5±9.19	1.65±0.05	<0.0001
trlE7EPC6	CD44	20.93±1.51	15.41±0.38	14.5±0.71	5.85±0.19	<0.0001
splP16615-5	ATP2A2	48.62±5.43	30.59±3.83	32.5±0.71	2.10±0.18	<0.0001
splO43175	PHGDH	42.32±4.59	56.01±6.50	43.5±4.94	4.43±1.80	0.0004
splQ07065	CKAP4	37.42±3.34	37.13±0.12	23.5±2.12	1.84±0.07	0.0084
splP05556	ITGB1	34.97±1.27	25.50±0.27	22.5±3.54	2.35±0.33	0.0002
splQ9Y6N5	SQRDL	33.74±1.28	44.56±4.24	20.0±1.41	2.12±0.18	0.0007
splQ13501	SQSTM1	31.33±1.22	63.41±0.00	25.5±2.12	4.04±0.08	0.0002
splP07355-2	ANXA2	75.77±0.13	72.13±1.39	135.5±9.19	1.86±0.04	0.0012
splP21980	TGM2	46.15±2.05	45.30±6.38	30.0±2.83	2.12±0.28	0.0002
trlH0Y323	CAPN2	49.09±2.84	48.01±5.43	34.5±3.54	2.39±1.14	0.0004
trlF5H0Q5	AHSG	8.43±0.08	6.93±0.00	22.0±0.00	4.06±0.11	0.0014
splQ13751	LAMB3	14.62±2.70	11.48±1.39	8.5±0.71	3.12±0.45	0.0018
splQ96AG4	LRRC59	24.42±0.61	48.21±0.00	15.0±1.41	2.76±0.29	0.0006
splP37802	TAGLN2	48.05±5.01	75.88±0.71	76.5±0.71	4.01±1.16	0.0014
splO15231	ZNF185	6.63±0.86	10.45±1.44	3.5±0.71	3.60±0.05	0.0145
splP08670	VIM	78.14±2.44	69.52±0.30	128.5±2.12	6.78±0.66	0.0009
splP07203	GPX1	27.36±0.85	84.24±0.00	17.5±0.71	4.32±0.48	0.0013
splP46060	RANGAP1	44.64±3.22	53.24±0.12	28.5±0.71	1.66±0.02	0.0079
splO00159-2	MYO1C	51.34±4.12	34.29±0.48	30.5±4.95	3.26±1.68	0.0058
splP04083	ANXA1	52.37±6.22	68.64±1.02	91.5±9.19	1.84±0.17	0.0033
splQ92597	NDRG1	20.49±0.41	37.82±0.00	20.0±1.41	3.36±1.03	0.0019
trlB4E0H8	ITGA3	23.64±2.69	16.20±2.59	16.5±3.54	2.09±0.54	0.0087
trlE7ESU5	ALB	33.95±4.02	41.66±1.03	72.5±6.36	2.26±0.13	0.0023
trlD6RAK8	GC	9.94±2.45	17.95±1.29	10.0±1.41	4.52±0.82	0.0036
trlQ5T985	ITIH2	11.62±0.23	9.68±0.68	9.0±0.00	3.99±2.19	0.0080
splP26639	TARS	77.47±5.34	57.74±1.27	68.5±2.12	2.26±0.32	0.0040
splP49589-3	CARS	38.44±3.73	32.61±4.94	18.0±2.90	2.12±0.10	0.0176
trlF5H7K4	NCEH1	17.57±0.62	26.90±0.79	10.5±0.71	2.25±0.61	0.0241
splP02788	LTF	8.71±1.27	9.86±0.00	12.5±0.71	7.29±0.62	0.0188
splQ92621	NUP205	33.73±1.67	12.23±2.81	20.5±3.54	2.33±0.29	0.0318
splQ9NZM1-6	MYOF	140.84±3.56	47.85±2.60	87.0±4.24	2.24±0.16	0.0062
splQ9Y2T3-3	GDA	39.77±1.44	59.45±0.00	38.0±1.41	3.18±0.40	0.0062
splP29317	EPHA2	15.51±5.52	11.99±2.03	10.0±1.41	3.46±0.34	0.0083
splP80723	BASP1	25.19±1.68	72.03±4.05	27.0±1.41	7.59±2.89	0.0101
splP48681	NES	23.27±1.01	10.73±0.87	12.5±0.71	2.86±0.11	0.0240
splP31947	SFN	20.68±0.27	67.34±1.71	37.0±1041	2.37±0.65	0.0190
splP16144-4	ITGB4	41.89±1.24	18.83±0.69	25.5±0.71	1.81±0.01	0.0364
splQ01995	TAGLN	6.56±2.14	25.13±3.88	5.0±1.41	2.31±0.35	0.0373
splQ6P9B6	KIAA1609	8.96±1.87	16.01±0.62	6.0±1.41	3.02±0.20	0.0326

Table II. Continued.

B, Downregulated differentially expressed proteins						
Accession	Protein	Unused score ^a	Coverage, % ^a	Peptide 95% CL ^a	iTRAQ rate ^a	P-value ^a
splA0MZ66	KIAA1598	50.71±0.09	51.74±0.78	31.0±2.12	0.58±0.04	0.0011
splO00232	PSMD12	35.44±1.51	47.03±2.02	24.0±2.83	0.47±0.04	0.0029
splO14818	PSMA7	29.16±1.11	62.70±0.28	23.0±2.83	0.47±0.09	0.0237
splO60749	SNX2	20.85±4.76	29.57±4.22	16.0±2.12	0.51±0.03	0.0015
splO75533	SF3B1	69±0.34	36.5±2.60	40.0±1.41	0.41±0.00	0.0014
splO95347	SMC-2	56.22±3.49	30.91±2.01	37.0±4.95	0.58±0.04	0.0068
splO95573	ACSL3	35.36±1.34	36.04±0.10	21.0±2.83	0.58±0.07	0.0096
splO95861	BPNT1	23.27±0.62	56.82±0.92	15.0±0.71	0.49±0.20	0.0206
splP00390	GSR	17.07±0.64	32.47±3.11	11.0±0.00	0.45±0.16	0.0018
splP00505	GOT2	53.15±1.19	66.62±0.16	39.0±4.24	0.53±0.02	0.0172
splP04040	CAT	34.55±2.03	48.29±2.81	22.0±0.71	0.49±0.01	0.0015
splP04075	ALDOA	97.5±2.79	87.23±1.36	212.0±7.07	0.50±0.02	0.0011
splP04792	HSPB1	41.05±1.21	79.51±8.28	53.0±1.41	0.23±0.23	0.0034
splP05455	SSB	41.26±0.87	51.10±1.21	26.0±1.41	0.49±0.03	0.0034
splP06744	GPI	51.08±0.08	55.19±1.52	65.0±4.24	0.41±0.10	0.0078
splP07195	LDHB	33.47±2.41	65.72±4.48	73.0±1.41	0.32±0.12	0.0161
splP07339	CTSD	33.9±0.68	50.85±4.98	36.0±2.12	0.54±0.04	0.0010
splP07942	LAMB1	42.6±3.96	18.47±1.27	27.0±3.54	0.54±0.06	0.0215
splP07954	FH	38.99±0.31	50.09±0.42	37.0±2.12	0.58±0.05	0.0065
splP09972	ALDOC	32.73±1.24	70.05±2.33	96.0±0.00	0.21±0.01	0.0020
splP11586	MTHFD1	76.09±4.05	50.16±4.99	53.0±3.54	0.60±0.04	0.0055
splP12004	PCNA	27.15±3.05	58.62±2.16	37.0±3.54	0.61±0.04	0.0032
splP13611-2	VCAN	25.2±1.73	8.053±0.53	17.0±0.71	0.37±0.12	0.0065
splP13797	PLS3	74.13±3.57	67.69±1.01	69.0±4.95	0.24±0.07	0.0037
splP21266	GSTM3	33.26±1.87	72.22±3.46	21.0±1.41	0.38±0.04	0.0050
splP23786	CPT2	27.57±5.16	33.06±5.06	17.0±3.54	0.61±0.04	0.0274
splP25789	PSMA4	27.86±0.86	65.13±1.63	32.0±4.95	0.58±0.00	0.0133
splP27824	CANX	57.96±1.73	62.92±3.71	53.0±0.71	0.31±0.10	0.0016
splP37268	FDFT1	17.91±0.20	32.85±2.71	12.0±2.12	0.30±0.10	0.0052
splP40937	RFC5	14.34±1.11	27.06±3.75	12.0±2.12	0.48±0.02	0.0278
splP42166	TMPO	48.96±6.58	57.28±2.55	35.0±3.54	0.28±0.04	0.0004
splP42704	LRPPRC	129.11±3.57	58.21±3.70	95.0±12.02	0.44±0.09	0.0003
splP48449	LSS	28.14±3.34	26.57±0.10	16.0±0.71	0.43±0.07	0.0314
splP48735	IDH2	36.91±0.72	44.02±4.38	21.0±0.71	0.49±0.07	0.0010
splP49321	NASP	50.23±3.21	55.08±2.87	38.0±2.12	0.29±0.00	0.0175
splP49327	FASN	200.88±9.07	56.81±0.37	167.0±3.54	0.21±0.01	<0.0001
splP49419	ALDH7A1	40.15±4.71	48.24±0	32.0±3.54	0.49±0.00	0.0238
splP51659	HSD17B4	48.92±2.98	50.87±0.86	36.0±4.95	0.47±0.06	0.0345
splP52209	PGD	60±8.37	66.97±9.81	54.0±4.24	0.48±0.11	0.0226
splP52943	CRIP2	16.69±0.41	44.47±2.38	12.0±1.41	0.58±0.11	0.0371

^aPresented as mean ± standard deviation. CL, confidence level; iTRAQ, isobaric tag for relative and absolute quantitation.

proteins may have been directly or indirectly regulated by miR-148a.

Verification of iTRAQ MS results using RT-qPCR and western blotting. Among the globally dysregulated group




Figure 2. Heat map of 84 differentially expressed proteins in SPC-A-1 cells transfected with a microRNA-148a-inhibitor compared with cells transfected with a control oligonucleotide as determined by 2 identical mass spectrometry experiments.

of miR-148a-regulated proteins, a number of the proteins, including IDH2 (27), PHGDH (28), VIM (29), SLC3A2 (30), ACTN4 (31), MYH9 (32), ITGB1 (33), LAMB3 (34), were previously associated with migration in cancer cells. To verify the iTRAQ results, the mRNA levels of eight of the upregulated proteins (including MYH9, CD44, ITGB1, LAMB3, PHGDH, ACTN4, LMNA and VIM) and eight of the downregulated proteins (including PSMA7, MTHFD1, GSTM3, FH, HSPB1, LRPPRC, CPT2 and IDH2) were determined by RT-qPCR. As illustrated in Fig. 3A, the expression of the 16 genes was consistent with the MS analysis. Similar results were also demonstrated for the protein levels of LAMB3, VIM, PHGDH, ACTN4, FH,

HSPB1, IDH2, LDHB, FASN and CAT, as revealed by WB analysis (Fig. 3B).

Functional enrichment of miR-148a-regulated proteins. As demonstrated in Table III, the most significantly enriched KEGG pathways for the differentially expressed proteins were 'focal adhesion', 'arrhythmogenic right ventricular cardiomyopathy (ARVC)', 'ECM-receptor interaction', 'glutathione metabolism' and 'small cell lung cancer'. The proteins associated with each pathway are displayed in Table III.

GO annotation included the biological process, cellular component and molecular function GO categories. In

Table III. Significantly enriched Kyoto Encyclopedia of Genes and Genomes pathways associated with the identified differentially expressed proteins.

Pathway	Count	P-value	Associated genes
Arrhythmogenic right ventricular cardiomyopathy	6	0.0007	ATP2A2, ACTN4, LMNA, ITGB4, ITGA3, ITGB1
ECM-receptor interaction	6	0.0012	LAMB3, CD44, ITGB4, ITGA3, LAMB1, ITGB1
Glutathione metabolism	5	0.0013	GSR, GPX1, GSTM3, PGD, IDH2
Pentose phosphate pathway	4	0.0017	ALDOA, GPI, ALDOC, PGD
Glycolysis/Gluconeogenesis	5	0.0025	ALDOA, GPI, LDHB, ALDH7A1, ALDOC
Hypertrophic cardiomyopathy (HCM)	5	0.0087	ATP2A2, LMNA, ITGB4, ITGA3, ITGB1
Dilated cardiomyopathy	5	0.0114	ATP2A2, LMNA, ITGB4, ITGA3, ITGB1
Focal adhesion	7	0.0120	LAMB3, ACTN4, ITGB4, ITGA3, LAMB1, CAPN2, ITGB1
Small cell lung cancer	4	0.0465	LAMB3, ITGA3, LAMB1, ITGB1

ATP2A2, ATPase sarcoplasmic/endoplasmic reticulum Ca²⁺ transporting 2; ACTN4, α -actinin 4; LMNA, lamin A/C; ITGB4, integrin subunit β 4; ITGA3, integrin subunit α 3; ITGB1, integrin subunit β 1; LAMB3, laminin subunit β 3; CD44, cluster of differentiation 44; LAMB1, laminin subunit β 1; GSR, glutathione-disulfide reductase; GPX1, glutathione peroxidase 1; GSTM3, glutathione S-transferase μ 3; PGD, phosphogluconate dehydrogenase; IDH2, isocitrate dehydrogenase (NADP⁺) 2; ALDOA, aldolase, fructose-bisphosphonate A; GPI, glucose-6-phosphate isomerase; ALDOC, aldolase, fructose-bisphosphonate C; ALDH7A1, aldehyde dehydrogenase 7 family member A1; CAPN2, caplain 2.




Figure 3. Identified differentially expressed proteins verification by RT-qPCR and western blot analysis. (A) MicroRNA levels of 8 upregulated proteins (MYH9, CD44, ITGB1, LAMB3, PHGDH, ACTN4, LMNA and VIM) and 8 downregulated proteins (PSMA7, MTHFD1, GSTM3, FH, HSPB1, LRPPRC, CPT2 and IDH2) were determined by RT-qPCR following the transfection of SPC-A-1 cells with an miR-148a inhibitor or control oligonucleotide. β -actin served as an internal control. (B) Protein levels of LAMB3, VIM, PHGDH, ACTN4, FH, HSPB1, IDH2, LDHB, FASN and CAT were determined by western blot analysis following the transfection of SPC-A-1 cells with a miR-148a inhibitor or control oligonucleotide. β -actin served as an internal control. The data were representative of three independent experiments. * P <0.05. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; MYH9, myosin heavy chain 9; CD44, cluster of differentiation 44; ITGB1, integrin β 1; LAMB3, laminin subunit β 3; PHGDH, phosphoglycerate dehydrogenase; ACTN4, α -actinin-4; LMNA, lamin A/C; VIM, vimentin; PSMA7, proteasome subunit α 7; MTHFD1, methylenetetrahydrofolate dehydrogenase; GSTM3, glutathione S-transferase M3; FH, fumarate hydratase; HSPB1, heat shock protein β 1; LRPPRC, leucine rich pentatricopeptide repeat; CPT2, carnitine palmitoyltransferase 2; IDH2, isocitrate dehydrogenase 2; LDHB, lactate dehydrogenase B; FASN, fatty acid synthase; CAT, catalase.

Biological Process, the top 3 were 'oxidation reduction', 'coenzyme metabolic process' and 'cofactor metabolic process'. In cellular component, differentially expressed proteins were most likely to be associated with

'mitochondrion', 'organelle envelope', 'envelope' and 'cell fraction'. Molecular Function analysis indicated that the proteins were chiefly involved in 'identical protein binding', 'cofactor binding', 'cytoskeletal protein binding' and 'actin




Figure 4. The 84 differentially expressed proteins were uploaded to the Database for Annotation, Visualization and Integrated Discovery for GO analysis. The histograms demonstrate the top 10 terms by count for (A) biological process, (B) cellular component and (C) molecular function. GO, Gene Ontology.

binding'. The results of GO annotation are illustrated in Fig. 4.

Protein-protein interaction network. To elucidate the protein-protein interactions of the globally differentially expressed proteins in the SPC-A-1 cells treated with a miR-148a inhibitor, a STRING database search was performed. The database identified interactions for 81 proteins at the medium confidence level (STRING score, 0.4). The network is displayed in Fig. 5.

GO analysis in STRING revealed that the GO terms most significantly associated with the differentially expressed proteins in the network were 'small molecule metabolic process', 'epithelium development', 'carboxylic acid metabolic process', 'oxoacid metabolic process' and 'organonitrogen compound metabolic process'. GSR, IDH2, ALDH7A1, GOT2, PMSA4 and PMSA7 were associated with 'small molecule metabolic process', VIM, LAMB3, CAT, TAGLN and TAGLN2 with 'epithelium development' and CARS, TARS, GPI, ALDOA and PGD with 'carboxylic acid metabolic process'.

Discussion

It has been identified that miR-148a serves important functions in various types of cancer (35,36). Our previous study demonstrated that miR-148a exerted metastasis-suppressive effects in NSCLC, suppressing NSCLC invasion and metastasis *in vitro* and *in vivo* (19). These results have been corroborated

by other studies (21,37), indicating that miR-148a may provide a promising therapeutic target against NSCLC. However, the molecular mechanisms underlying the metastasis-suppressive effects of miR-148a on NSCLC remain poorly understood. An increasing number of researchers employ proteomic strategies to seek downstream putative targets and molecular mechanisms modulated by miRNAs (16-18). In the present study, iTRAQ technology combined with NanoLC-MS/MS was used to analyze the global protein expression profiles of SPC-A-1 cells treated with the miR-148a inhibitor and control, and therefore, to explore the molecular mechanisms modulated by miR-148a. A total of 84 differentially expressed proteins were identified, of which 44 proteins were upregulated and 40 were downregulated. A number of these miR-148a-regulated proteins may be associated with cancer migration.

The protein expression levels of four upregulated proteins (LAMB3, VIM, PHGDH and ACTN4) and six downregulated proteins (FH, HSPB1, IDH2, LDHB, FASN and CAT) were examined by WB analysis; all results were consistent with the MS results. LAMB3 is a member of the laminin family of large glycoproteins, present in various types of basement membrane (BM) (38). LAMB3 is associated with the metastasis of a number of types of tumor (39-41). Concordantly, our previous study (34) demonstrated that the protein expression level of LAMB3 was higher in NSCLC compared with non-cancerous adjacent tissues and that LAMB3 expression was associated with lymphatic metastasis. LAMB3 may be a suitable therapeutic target in NSCLC. Vimentin is responsible for maintaining cell shape and integrity of the cytoplasm, and stabilizing cytoskeletal interactions. It is a vital mesenchymal marker that participates in the endothelial-mesenchymal transition (EndMT) and tumor metastasis (42). The upregulation of vimentin in NSCLC was detected in a previous study (43). PHGDH is an enzyme that catalyzes the NAD^+ -dependent conversion of 3-phosphoglycerate to phosphohydroxypyruvate. The conversion is the first step in the *de novo* serine synthesis pathway (44). In patients with gastric cancer, high PHGDH protein expression is associated with a poor prognosis (45). In addition, PHGDH expression may promote tumor initiation and metastasis in breast cancer (28). However, the functions of PHGDH in NSCLC are not clear. ACTN4 participates in the formation of the filopodia and lamellipodia, which are important for cell motility, by regulating the flexibility of actin filaments (46). It has been reported that ACTN4 may promote the metastatic potential of lung cancer (31).

With regard to the six verified downregulated proteins, IDH2 is a mitochondrial NADP -dependent isocitrate dehydrogenase that functions variably in different types of cancer. It has been reported that IDH2 inhibited the invasion of hepatocellular carcinoma cells via the regulation of MMP9, and therefore acted as a tumor suppressor (47). By contrast, in another study the overexpression of IDH2 promoted cell growth in colon cancer (48). It has been suggested that FH suppresses the tumorigenesis, development and invasion of various types of cancer (49). FH mRNA expression and protein expression have been observed to be significantly lower in lung cancer cells and tissue samples (50). However, the molecular mechanisms for the tumor suppressive functions of FH are uncharacterized. HSPB1 has been reported as a multifunctional molecule; for example, the expression level of HSPB1 is higher

lung cancer, and although DNMT was detected in the present study, there was no alteration to its expression subsequent to the inhibition of miR-148a. The lack of difference in DNMT1 protein expression in the present study may be a discrepancy caused by tumor heterogeneity. Despite the progress in understanding the molecular mechanisms of miR-148a and its function in different types of cancer, the topic remains ambiguous, and further investigation is required.

In the present study, differentially expressed proteins were identified using a proteomics strategy in SPC-A-1 cells after transfection with the miR-148a inhibitor; the differentially expressed proteins were then analyzed using bioinformatics tools. The results may provide a deeper insight into the molecular mechanisms underlying the metastasis-suppressive effect of miR-148a on NSCLC. The targets of miR-148a may directly or indirectly interact with tumor-associated proteins to affect the metastasis of NSCLC via the pathways identified in the bioinformatics analysis. The present study also supports the possibility that miR-148a may be a potential therapeutic target against NSCLC.

Acknowledgements

The present study was supported by the Shanghai Natural Science Foundation (grant no. 12ZR1428900) and the State Key Laboratory of Oncogenes and Related Genes Research Fund (grant no. 91-15-09).

References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. *CA Cancer J Clin* 65: 87-108, 2015.
- Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer statistics for Hispanics/Latinos, 2015. *CA Cancer J Clin* 65: 457-480, 2015.
- Mizuno K, Mataka H, Seki N, Kumamoto T, Kamikawaji K and Inoue H: MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. *J Hum Genet* 62: 57-65, 2016.
- Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. *Mayo Clin Proc* 83: 584-594, 2008.
- Hanahan D and Weinberg RA: The hallmarks of cancer. *Cell* 100: 57-70, 2000.
- Ambros V: The functions of animal microRNAs. *Nature* 431: 350-355, 2004.
- Bartel DP: MicroRNAs: Target recognition and regulatory functions. *Cell* 136: 215-233, 2009.
- Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, *et al*: MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. *Oncogene* 34: 413-423, 2015.
- Xue J, Chi Y, Chen Y, Huang S, Ye X, Niu J, Wang W, Pfeffer LM, Shao ZM, Wu ZH and Wu J: MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. *Oncogene* 35: 448-458, 2016.
- Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 9: 852, 2017.
- Shen B, Yu S, Zhang Y, Yuan Y, Li X, Zhong J and Feng J: miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway. *Onco Targets Ther* 9: 6009-6019, 2016.
- Li J, Wu H, Li W, Yin L, Guo S, Xu X, Ouyang Y, Zhao Z, Liu S, Tian Y, *et al*: Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF- κ B signaling. *Oncogene* 35: 5501-5514, 2016.
- Ai J, Huang H, Lv X, Tang Z, Chen M, Chen T, Duan W, Sun H, Li Q, Tan R, *et al*: FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. *Cell Physiol Biochem* 27: 207-216, 2011.
- Mueller LN, Brusniak MY, Mani DR and Aebersold R: An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. *J Proteome Res* 7: 51-61, 2008.
- Lin HC, Zhang FL, Geng Q, Yu T, Cui YQ, Liu XH, Li J, Yan MX, Liu L, He XH, *et al*: Quantitative proteomic analysis identifies CPNE3 as a novel metastasis-promoting gene in NSCLC. *J Proteome Res* 12: 3423-3433, 2013.
- Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Röh S, Hoffmann R, Warscheid B and Hermeking H: Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. *Mol Cell Proteomics* 10: M111.010462, 2011. doi: 10.1074/mcp.M111.010462.
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP: The impact of microRNAs on protein output. *Nature* 455: 64-71, 2008.
- Litholdo CG Jr, Parker BL, Eamens AL, Larsen MR, Cordwell SJ and Waterhouse PM: Proteomic identification of putative microRNA394 target genes in arabidopsis thaliana identifies major latex protein family members critical for normal development. *Mol Cell Proteomics* 15: 2033-2047, 2016.
- Li J, Yu T, Cao J, Liu L, Liu Y, Kong HW, Zhu MX, Lin HC, Chu DD, Yao M and Yan MX: MicroRNA-148a suppresses invasion and metastasis of human non-small-cell lung cancer. *Cell Physiol Biochem* 37: 1847-1856, 2015.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
- Joshi P, Jeon YJ, Lagana A, Middleton J, Secchiero P, Garofalo M and Croce CM: MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. *Proc Natl Acad Sci USA* 112: 8650-8655, 2015.
- Zhu A, Xia J, Zuo J, Jin S, Zhou H, Yao L, Huang H and Han Z: MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. *Med Oncol* 29: 2701-2709, 2012.
- Zhang SL and Liu L: MicroRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. *Exp Ther Med* 9: 579-584, 2015.
- Zhang R, Li M, Zang W, Chen X, Wang Y, Li P, Du Y, Zhao G and Li L: miR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. *Tumour Biol* 35: 837-844, 2014.
- Jiang Q, He M, Ma MT, Wu HZ, Yu ZJ, Guan S, Jiang LY, Wang Y, Zheng DD, Jin F and Wei MJ: MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. *Oncol Rep* 35: 1425-1432, 2016.
- Sakamoto N, Naito Y, Oue N, Sentani K, Uraoka N, Zarni Oo H, Yanagihara K, Aoyagi K, Sasaki H and Yasui W: MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis. *Cancer Sci* 105: 236-243, 2014.
- Yi WR, Li ZH, Qi BW, Ernest ME, Hu X and Yu AX: Down-regulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF- κ B and MMP-9 activation. *Oncol Rep* 35: 2277-2285, 2016.
- Samanta D, Park Y, Andrabi SA, Shelton LM, Gilkes DM and Semenza GL: PHGDH expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance and lung metastasis. *Cancer Res* 76: 4430-4442, 2016.
- Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, *et al*: Vimentin is a novel AKT1 target mediating motility and invasion. *Oncogene* 30: 457-470, 2011.
- Chen CL, Chung T, Wu CC, Ng KF, Yu JS, Tsai CH, Chang YS, Liang Y, Tsui KH and Chen YT: Comparative tissue proteomics of microdissected specimens reveals novel candidate biomarkers of bladder cancer. *Mol Cell Proteomics* 14: 2466-2478, 2015.
- Gao Y, Li G, Sun L, He Y, Li X, Sun Z, Wang J, Jiang Y and Shi J: ACTN4 and the pathways associated with cell motility and adhesion contribute to the process of lung cancer metastasis to the brain. *BMC Cancer* 15: 277, 2015.
- Zhou W, Fan MY, Wei YX, Huang S, Chen JY and Liu P: The expression of MYH9 in osteosarcoma and its effect on the migration and invasion abilities of tumor cell. *Asian Pac J Trop Med* 9: 597-600, 2016.
- Qin Q, Wei F, Zhang J and Li B: miR-134 suppresses the migration and invasion of non-small cell lung cancer by targeting ITGB1. *Oncol Rep* 37: 823-830, 2017.

34. Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, Lin HC, He XH, Li JJ and Yao M: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. *PLoS One* 8: e55714, 2013.
35. Zhang H, Wang Y, Xu T, Li C, Wu J, He Q, Wang G, Ding C, Liu K, Tang H and Ji F: Increased expression of microRNA-148a in osteosarcoma promotes cancer cell growth by targeting PTEN. *Oncol Lett* 12: 3208-3214, 2016.
36. Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM and Mudryj M: miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. *Mol Carcinog* 55: 757-767, 2016.
37. Li J, Song Y, Wang Y, Luo J and Yu W: MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. *Mol Cell Biochem* 380: 277-282, 2013.
38. Simon-Assmann P, Orend G, Mammadova-Bach E, Spenlé C and Lefebvre O: Role of laminins in physiological and pathological angiogenesis. *Int J Dev Biol* 55: 455-465, 2011.
39. Tanis T, Cincin ZB, Gokcen-Rohlig B, Bireller ES, Ulasan M, Tanyel CR and Cakmakoglu B: The role of components of the extracellular matrix and inflammation on oral squamous cell carcinoma metastasis. *Arch Oral Biol* 59: 1155-1163, 2014.
40. Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. *Int J Oncol* 42: 1523-1532, 2013.
41. Kinoshita T, Hanazawa T, Nohata N, Kikkawa N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto Y and Seki N: Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. *Oncotarget* 3: 1386-1400, 2012.
42. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. *Cell* 139: 871-890, 2009.
43. Tadokoro A, Kanaji N, Liu D, Yokomise H, Haba R, Ishii T, Takagi T, Watanabe N, Kita N, Kadowaki N and Bandoh S: Vimentin regulates invasiveness and is a poor prognostic marker in non-small cell lung cancer. *Anticancer Res* 36: 1545-1551, 2016.
44. Unterlass JE, Basle A, Blackburn TJ, Tucker J, Cano C, Noble ME and Curtin NJ: Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. *Oncotarget*, 13139-13153, 2018.
45. Xian Y, Zhang S, Wang X, Qin J, Wang W and Wu H: Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer. *Onco Targets Ther* 9: 5553-5560, 2016.
46. Shao H, Wang JH, Pollak MR and Wells A: α -actinin-4 is essential for maintaining the spreading, motility and contractility of fibroblasts. *PLoS One* 5: e13921, 2010.
47. Tian GY, Zang SF, Wang L, Luo Y, Shi JP and Lou GQ: Isocitrate dehydrogenase 2 suppresses the invasion of hepatocellular carcinoma cells via matrix metalloproteinase 9. *Cell Physiol Biochem* 37: 2405-2414, 2015.
48. Lv Q, Xing S, Li Z, Li J, Gong P, Xu X, Chang L, Jin X, Gao F, Li W, *et al*: Altered expression levels of IDH2 are involved in the development of colon cancer. *Exp Ther Med* 4: 801-806, 2012.
49. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, *et al*: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 30: 406-410, 2002.
50. Ming Z, Jiang M, Li W, Fan N, Deng W, Zhong Y, Zhang Y, Zhang Q and Yang S: Bioinformatics analysis and expression study of fumarate hydratase in lung cancer. *Thorac Cancer* 5: 543-549, 2014.
51. Cai XZ, Zeng WQ, Xiang Y, Liu Y, Zhang HM, Li H, She S, Yang M, Xia K and Peng SF: iTRAQ-based quantitative proteomic analysis of nasopharyngeal carcinoma. *J Cell Biochem* 116: 1431-1441, 2015.
52. Choi SH, Nam JK, Kim BY, Jang J, Jin YB, Lee HJ, Park S, Ji YH, Cho J and Lee YJ: HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis. *Cancer Res* 76: 1019-1030, 2016.
53. Potenta S, Zeisberg E and Kalluri R: The role of endothelial-to-mesenchymal transition in cancer progression. *Br J Cancer* 99: 1375-1379, 2008.
54. Lin F, Wang N and Zhang TC: The role of endothelial-mesenchymal transition in development and pathological process. *IUBMB Life* 64: 717-723, 2012.
55. Augsten M: Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. *Front Oncol* 4: 62, 2014.
56. Zeisberg EM, Potenta S, Xie L, Zeisberg M and Kalluri R: Discovery of endothelial-to-mesenchymal transition as a source for carcinoma-associated fibroblasts. *Cancer Res* 67: 10123-10128, 2007.
57. Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R and Tosato G: Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through notch-dependent signaling. *Cancer Res* 72: 1157-1169, 2012.
58. Krizbai IA, Gasparics Á, Nagyörsi P, Fazakas C, Molnár J, Wilhelm I, Bencs R, Rosivall L and Sebe A: Endothelial-mesenchymal transition of brain endothelial cells: Possible role during metastatic extravasation. *PLoS One* 10: e0123845, 2015.
59. van Meeteren LA and ten Dijke P: Regulation of endothelial cell plasticity by TGF- β . *Cell Tissue Res* 347: 177-186, 2012.
60. Cui J, Quan M, Jiang W, Hu H, Jiao F, Li N, Jin Z, Wang L, Wang Y and Wang L: Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. *Med Oncol* 32: 143, 2015.
61. Li C, Chen Y, Bai P, Wang J, Liu Z, Wang T and Cai Q: LDHB may be a significant predictor of poor prognosis in osteosarcoma. *Am J Transl Res* 8: 4831-4843, 2016.
62. Wang J, Zhang X, Shi J, Cao P, Wan M, Zhang Q, Wang Y, Kridel SJ, Liu W, Xu J, *et al*: Fatty acid synthase is a primary target of miR-15a and miR-16-1 in breast cancer. *Oncotarget* 7: 78566-78576, 2016.
63. Cerne D, Zitnik IP and Sok M: Increased fatty acid synthase activity in non-small cell lung cancer tissue is a weaker predictor of shorter patient survival than increased lipoprotein lipase activity. *Arch Med Res* 41: 405-409, 2010.
64. Tsai JY, Lee MJ, Dah-Tsyr Chang M and Huang H: The effect of catalase on migration and invasion of lung cancer cells by regulating the activities of cathepsin S, L and K. *Exp Cell Res* 323: 28-40, 2014.
65. Zhang W and Xu J: DNA methyltransferases and their roles in tumorigenesis. *Biomark Res* 5: 1, 2017.
66. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, Qi YT, Xu Q, Li W, Lu B, *et al*: A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumorangiogenesis through IGF-IR and IRS1. *J Mol Cell Biol* 5: 3-13, 2013.